Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2023-03-01 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰2023年度向特定对象发行A股股票募集资金使用的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023年度向特定对象发行A股股票募集资金使用的可行性分析报告" which translates to "2023 Feasibility Analysis Report on the Use of Funds Raised by Private Placement of A Shares." It details the company's plan to raise capital through a specific issuance of shares, describing the intended use of the raised funds, including new drug R&D, expansion projects, and working capital. The document includes detailed investment plans, project feasibility, policy support, and impact on company financials. This is a capital raising and financing update document, not a full annual or interim report, nor an earnings release or management discussion. It is not a regulatory filing or announcement of a report but a substantive report on capital raising and fund usage. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (9135 characters) and content support this classification with high confidence.
2023-03-01 Chinese
百奥泰关于本次募集资金投向属于科技创新领域的说明
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation from Bio-Thera Solutions, Ltd. regarding the allocation of funds raised from a specific stock issuance. It extensively discusses the company's business, the use of proceeds from the fundraising, including new drug R&D projects, expansion projects, and working capital. The document references regulatory frameworks related to securities issuance and innovation funding, and it is dated March 2023. The content focuses on the use of capital raised and its alignment with technology innovation policies. This is a capital/financing update document explaining the use of proceeds from a fundraising event, not a full financial report or earnings release. It is not an announcement of a report publication but a substantive disclosure about capital use. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-03-01 Chinese
百奥泰未来三年（2024年—2026年）股东回报规划
Notice of Dividend Amount Classification · 95% confidence The document is titled "Future Three-Year (2024-2026) Shareholder Return Plan" issued by Bio-Thera Solutions, Ltd. It details the company's planned profit distribution policies, including cash dividends, stock dividends, decision-making procedures, and mechanisms for shareholder returns over the next three years. The content focuses on dividend policy and shareholder return strategy rather than reporting actual financial results or earnings. It is a formal announcement of the company's dividend and shareholder return planning, not a financial report or earnings release. The document length is 3713 characters, which is relatively short and consistent with a policy announcement rather than a full report. Therefore, this document fits best under the category of Notice of Dividend Amount (DIV) as it outlines dividend distribution plans and policies for shareholders.
2023-03-01 Chinese
百奥泰 第二届监事会第五次会议决议的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed by the Supervisory Board (监事会) of 百奥泰生物制药股份有限公司 regarding a proposed issuance of A shares to specific investors. It includes detailed information about the issuance plan, pricing, number of shares, use of proceeds, lock-up period, and compliance with relevant laws and regulations. The document is a formal announcement of decisions made by the Supervisory Board and is intended to be submitted to the shareholders' meeting for approval. It does not contain financial statements or quarterly/annual financial results, nor is it a transcript, audit report, or management discussion. The content focuses on capital raising activities and the issuance of new shares to specific investors, which aligns with the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing plan, not merely a brief announcement or a report publication notice. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2023-03-01 Chinese
百奥泰 关于向特定对象发行A股股票摊薄即期回报与公司采取填补措施及相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 百奥泰生物制药股份有限公司 regarding a specific issuance of A shares to certain investors. It includes detailed financial impact analysis on earnings per share, assumptions for the issuance, risk warnings about dilution of immediate returns, the necessity and rationale for the issuance, use of proceeds, and commitments from the board, senior management, and controlling shareholders to measures mitigating dilution effects. The document references regulatory guidelines and contains detailed financial projections and corporate governance commitments related to the issuance. This is a capital raising event with detailed disclosure about the issuance and its impact on shareholders. It is not a full annual or interim report, nor an earnings release or audit report. It is not a simple announcement of a report publication but a substantive disclosure about a financing activity. Therefore, the document fits best under Capital/Financing Update (CAP). The document length (7624 characters) and content confirm it is a full disclosure rather than a brief announcement or certification. Confidence is high due to the detailed financial and operational information about the share issuance and related commitments.
2023-03-01 Chinese
百奥泰 关于最近五年存在被证券监管部门和交易所采取处罚或采取监管措施情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 百奥泰生物制药股份有限公司 regarding regulatory penalties and supervisory measures taken against the company in the past five years by securities regulatory authorities and stock exchanges. It details specific regulatory warnings and corrective actions taken by the company. The document does not contain financial statements or detailed financial data, nor is it a report like an annual or interim report. It is a regulatory disclosure about compliance and regulatory history, which fits best under Regulatory Filings (RNS). The document length is short (1411 characters), and it is not a report publication announcement but a direct disclosure. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-03-01 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.